Skip to content

Study · Observational study · 2026

4 results

Sexual Safety Signals of Common Antidiabetic Drugs: Insights From FAERS Disproportionality Analysis.

Lin S, Ding X, Dang X, Zhan Q

Andrology26 Mar 2026

PMID41883294 (opens in a new tab)PMCIDPMC13432634 (opens in a new tab)DOI10.1111/andr.70222 (opens in a new tab)PepBankPUB-41883294
Read at sourcePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanObservational studySafety outcome

    In FAERS, semaglutide was linked to 49 erectile dysfunction reports.

    In plain wordsIn adverse event reports, semaglutide was linked to 49 reports of erection problems.

    Peptide
    Semaglutide
    Outcome
    Not applicableErectile dysfunction reports
    Study

    n: not reported in source

    Outcome group
    Sexual function · Reproductive and sexual health
    Studied dose
    Dose not stated

    Measurements

    Reports
    49 reports
    semaglutide

    Source sentences

    Summary
    We identified 49 semaglutide-, 54 sitagliptin-, and 42 dapagliflozin-associated erectile dysfunction reports.
    1 context sentence
    Summary · context
    This retrospective pharmacovigilance study was conducted using the FDA Adverse Event Reporting System. A disproportionality analysis was performed to evaluate the reporting frequency of erectile dysfunction associated with commonly prescribed antidiabetic medications. The reporting odds ratio served…
  2. 02HumanObservational studySafety outcome

    In FAERS, semaglutide showed a significant disproportionate erectile dysfunction reporting signal.

    In plain wordsIn adverse event reports, semaglutide was linked to a higher relative frequency of erection problems.

    Peptide
    Semaglutide
    Outcome
    IncreaseErectile dysfunction reporting signal
    Study

    n: not reported in source

    Outcome group
    Sexual function · Reproductive and sexual health
    Studied dose
    Dose not stated

    Measurements

    Reporting odds ratio
    1.53
    semaglutide
    Information component lower bound
    0.19
    semaglutide

    Source sentences

    Summary
    All three drugs demonstrated significant disproportionality signals: semaglutide (reporting odds ratio: 1.53, 95% confidence interval: 1.16-2.03; information component025 = 0.19)
    1 context sentence
    Summary · context
    This retrospective pharmacovigilance study was conducted using the FDA Adverse Event Reporting System. A disproportionality analysis was performed to evaluate the reporting frequency of erectile dysfunction associated with commonly prescribed antidiabetic medications. The reporting odds ratio served…
  3. 03HumanObservational studyOther

    In FAERS semaglutide reports, erectile dysfunction showed a random failure-type time-to-onset distribution.

    In plain wordsIn adverse event reports, erection problems linked to semaglutide appeared randomly across treatment rather than mainly soon after initiation.

    Peptide
    Semaglutide
    Outcome
    Not applicableErectile dysfunction time-to-onset pattern
    Study

    n: not reported in source

    Outcome group
    Sexual function · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Time-to-onset analysis indicated a random failure-type distribution for all three drugs (semaglutide, sitagliptin, and dapagliflozin),
    1 context sentence
    Summary · context
    This retrospective pharmacovigilance study was conducted using the FDA Adverse Event Reporting System. A disproportionality analysis was performed to evaluate the reporting frequency of erectile dysfunction associated with commonly prescribed antidiabetic medications. The reporting odds ratio served…
  4. 04HumanObservational studySafety outcome

    In FAERS, dulaglutide did not show a significant erectile dysfunction reporting signal.

    In plain wordsIn adverse event reports, dulaglutide showed no significant signal for erection problems.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changeErectile dysfunction reporting signal
    Study

    n: not reported in source

    Outcome group
    Sexual function · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Other agents in the same drug classes, including dulaglutide, linagliptin, and metformin, did not show significant signals.
    1 context sentence
    Summary · context
    This retrospective pharmacovigilance study was conducted using the FDA Adverse Event Reporting System. A disproportionality analysis was performed to evaluate the reporting frequency of erectile dysfunction associated with commonly prescribed antidiabetic medications. The reporting odds ratio served…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 2

    21 Oct 2026, 18:59 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.